{{Drugbox
| Verifiedfields=changed
| Watchedfields=changed
| verifiedrevid=458275071
| image=
<!-- Monoclonal antibody data -->
| type=mab
| mab_type=mab
| source=u
| target=[[TNF&alpha;]]
<!-- Clinical data -->
| tradename=Simponi
| Drugs.com={{drugs.com|monograph|golimumab}}
| MedlinePlus=a610010
| licence_EU=Simponi
| licence_US=Golimumab
| pregnancy_AU=
| pregnancy_US=
| pregnancy_category=
| legal_AU=
| legal_CA=
| legal_UK=
| legal_US=Rx-only
| legal_status=
| routes_of_administration=[[Subcutaneous injection]]
<!-- Pharmacokinetic data -->
| bioavailability=
| protein_bound=
| metabolism=
| elimination_half-life=
| excretion=
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number=476181-74-5
| ATC_prefix=L04
| ATC_suffix=AB06
| PubChem=
| DrugBank_Ref={{drugbankcite|correct|drugbank}}
| DrugBank=
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII=91X1KLU43E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG=D04358
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL=1201833
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID=none
<!-- Chemical data -->
| C=6530 | H=10068 | N=1752 | O=2026 | S=44
| molecular_weight=147 kg/mol
}}

'''Golimumab''' (CNTO 148)<ref>{{cite journal |last=Mazumdar |first=Sohini |author2=David Greenwald |title=Golimumab |journal=MAbs |year=2009 |volume=1 |issue=5 |pages=422–431 |doi=10.4161/mabs.1.5.9286 |url=http://www.landesbioscience.com/journals/mabs/article/9286/}}</ref> is a [[human]] [[monoclonal antibody]] which is used as an [[immunosuppressive drug]] and marketed under the brand name '''Simponi'''. Golimumab targets [[tumor necrosis factor alpha]] (TNF-alpha), a pro-inflammatory molecule<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/golimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab], ''American Medical Association''.</ref> and hence is a [[TNF inhibitor]].

Golimumab was developed by [[Janssen Biotech]], Inc. (formerly [[Centocor, Inc.|Centocor]] Biotech, Inc.) which also markets the product in the United States. The Janssen Pharmaceutical Companies market Simponi in Canada, Central and South America, the Middle East, Africa and Asia Pacific. In Europe, Russia and Turkey, Simponi distribution rights are held by Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. In Japan, Indonesia and Taiwan, distribution rights are held by Mitsubishi Tanabe Pharma Corporation.<ref>{{Cite web |url=http://www.jnj.com/news/all/SIMPONI-Receives-European-Commission-Approval-For-Treatment-Of-Non-Radiographic-Axial-Spondyloarthritis |title=SIMPONI® Receives European Commission Approval For Treatment Of Non-Radiographic Axial Spondyloarthritis {{!}} Johnson & Johnson |website=www.jnj.com |access-date=2016-05-09}}</ref>

==Development==
Golimumab binds to both soluble and transmembrane forms of TNFα. The antibody was isolated from a hybridoma clone produced by transgenic mice immunized with human TNFα. The golimumab-secreting clone was selected after being assayed for human light and heavy chains and TNFα-binding. The commercial product is produced in a recombinant cell line cultured by continuous perfusion.<ref>{{cite journal  |pmc=2759491 |year=2009 |author1=Mazumdar |first1=S |title=Golimumab |journal=MAbs |volume=1 |issue=5 |pages=422–431 |last2=Greenwald |first2=D |pmid=20065639}}</ref>

==Uses : Approvals and indications==
Golimumab is approved in Canada<ref>{{cite web |url=http://www.centocororthobiotech.com/cobi/viewDocumentByTitleAlias.html?title=PR_SIMPONI_CANADIAN_APPROVAL |title=Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis |format=|work=|accessdate=}}</ref> and the United States<ref name=D2009>{{Cite web |url=http://www.drugs.com/newdrugs/simponi-golimumab-receives-fda-approval-first-once-monthly-anti-tnf-rheumatoid-arthritis-psoriatic-1329.html |title=Simponi (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis |website=www.drugs.com |date=24 April 2009 |access-date=2016-05-09}}</ref> as a once monthly subcutaneous treatment for adults with moderately to severely active [[rheumatoid arthritis]], [[psoriatic arthritis]], and [[ankylosing spondylitis]].<ref name="ap">{{cite news|url=http://www.nctimes.com/business/article_95a13fa4-8492-5080-8ee0-bbce644fb21b.html |title=FDA clears potential blockbuster arthritis drug |work=[[North County Times]] |publisher=[[Lee Enterprises]] |agency=[[Associated Press]] |date=24 April 2009 |accessdate=23 October 2010 }}{{dead link|date=March 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name=CR2015>{{cite journal |last1=Maxwell |first1=LJ |last2=Zochling |first2=J |last3=Boonen |first3=A |last4=Singh |first4=JA |last5=Veras |first5=MM |last6=Tanjong Ghogomu |first6=E |last7=Benkhalti Jandu |first7=M |last8=Tugwell |first8=P |last9=Wells |first9=GA |title=TNF-alpha inhibitors for ankylosing spondylitis |journal=The Cochrane database of systematic reviews |date=18 April 2015 |volume=4 |issue=4 |pages=CD005468 |pmid=25887212 |doi=10.1002/14651858.CD005468.pub2}}</ref>

[[European Medicines Agency]] (EMA) has approved the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.<ref name=D2009/>{{failed verification|date=June 2017}} 

Golimumab was approved for the treatment by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA) in 2013 for the treatment of [[ulcerative colitis]].<ref>{{Cite journal|last=Löwenberg|first=Mark|last2=de Boer|first2=Nanne KH|last3=Hoentjen|first3=Frank|date=2014-03-12|title=Golimumab for the treatment of ulcerative colitis|journal=Clinical and Experimental Gastroenterology|volume=7|pages=53–59|doi=10.2147/CEG.S48741|issn=1178-7023|pmc=3958527|pmid=24648749}}</ref><ref>[http://sev.prnewswire.com/retail/20080415/NYTU07615042008-1.html Johnson & Johnson Reports 2008 First-Quarter Results]</ref>

==Clinical trials==
===Rheumatoid arthritis===
Large, double-blind [[randomized controlled trial]]s in patients with rheumatoid arthritis have shown that golimumab in combination with [[methotrexate]] was more effective than methotrexate alone.<ref name="golim">{{Cite journal |doi=10.2165/00063030-200923020-00005|pmid=19489653|title=Golimumab|journal=BioDrugs|volume=23|issue=2|pages=125|year=2009|last1=Oldfield|first1=Vicki|last2=Plosker|first2=Greg L.}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Johnson & Johnson]]
[[Category:Janssen Biotech]]
[[Category:TNF inhibitors]]